Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in J Am Acad Dermatol Retrieve available abstracts of 192 articles: HTML format

Single Articles

May 2025
1. PARIKH AK, Forman CA, Lipner SR
   Ethical considerations of treating melanoma anxiety in patients with obsessive-compulsive disorder.
   J Am Acad Dermatol. 2025 May 5:S0190-9622(25)00720.
   PubMed    
   
   
   
2. HAN Z, Hou J, Chang M
   Global Inequalities in the Burden of Melanoma From 1990 to 2021: Findings From the Global Burden of Disease Study 2021.
   J Am Acad Dermatol. 2025 May 3:S0190-9622(25)00690.
   PubMed    
   
   
   April 2025
3. KASHERI E, Sa B, Kraft G, Vattigunta M, et al
   Mapping Melanoma Mortality Hot Spots: A Geographic Spatial Analysis of Socioeconomic and Provider Disparities.
   J Am Acad Dermatol. 2025 Apr 25:S0190-9622(25)00680.
   PubMed    
   
   
   
4. MAI JZ, Sargen MR, Linet MS, Ike E, et al
   Impact of personal sun sensitivity and UV radiation on the association between blistering sunburns and melanoma.
   J Am Acad Dermatol. 2025 Apr 25:S0190-9622(25)00683.
   PubMed    
   
   
   
5. SCHONMANN Y, Cohen NT, Czarnowicki T
   Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study.
   J Am Acad Dermatol. 2025;92:741-752.
   PubMed     Abstract available
   
   
   March 2025
6. FAN X, Zhao Y, Zhao X
   Optimizing Melanoma Biopsy Practices: Implications for Clinical Accuracy and Patient Outcomes.
   J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00553.
   PubMed    
   
   
   
7. KHATTAB S, Beagles E, Tran M, Moseley C, et al
   Clinicopathologic Attributes and Downstream Outcomes of Mucosal Melanomas: A Multi-Hospital Cohort Study.
   J Am Acad Dermatol. 2025 Mar 28:S0190-9622(25)00548.
   PubMed    
   
   
   
8. MUNJAL A, Loeffler B, Fitzhugh M, Mani S, et al
   The impact of rurality and hospital proximity on melanoma staging during COVID-19: A retrospective cohort study.
   J Am Acad Dermatol. 2025 Mar 23:S0190-9622(25)00529.
   PubMed    
   
   
   
9. ADIGBLI G, Reed B, Khera B, Sangha M, et al
   Tumor-Infiltrating Lymphocyte Scoring Improves Progression Risk Prediction in Stage II Melanoma: A Retrospective Cohort Study.
   J Am Acad Dermatol. 2025 Mar 21:S0190-9622(25)00509.
   PubMed     Abstract available
   
   
   
10. TAYLOR MA, Sharma D, Fagan E, Ituarte B, et al
    Characterizing Cutaneous Head and Neck Melanoma in Pediatric Patients: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2025 Mar 17:S0190-9622(25)00448.
    PubMed    
    
    
    
11. FRANKEL D, Valdes-Morales K, Trifoi MD, Lin SK, et al
    Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: a retrospective cohort study.
    J Am Acad Dermatol. 2025 Mar 11:S0190-9622(25)00430.
    PubMed     Abstract available
    
    
    
12. KUMAR AB, Jakub JW, Lester SC, Markovic SN, et al
    In-transit melanoma metastases: Evaluation and Management for the Dermatologist.
    J Am Acad Dermatol. 2025 Mar 10:S0190-9622(25)00421.
    PubMed     Abstract available
    
    
    
13. ELSTON DM
    Letter from the editor: Desmoplastic melanoma behaves differently from other melanomas - American Joint Committee on Cancer staging should differ.
    J Am Acad Dermatol. 2025 Mar 6:S0190-9622(25)00397.
    PubMed    
    
    
    
14. JOSHI TP, Malhan P, Garcia N, Orengo IF, et al
    Melanoma-specific and overall survival in patients with single versus multiple primary melanoma: a national database study.
    J Am Acad Dermatol. 2025 Mar 3:S0190-9622(25)00391.
    PubMed    
    
    
    
15. THOMAS KM, Treichel AM, Herrera HO, Cullison CR, et al
    Psychological impact of a cutaneous melanoma diagnosis: A retrospective population-level cohort study.
    J Am Acad Dermatol. 2025;92:605-607.
    PubMed    
    
    
    February 2025
16. HIJAZ BA, Braun N, Reynolds K, Semenov YR, et al
    Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: A multi-center retrospective cohort study.
    J Am Acad Dermatol. 2025 Feb 28:S0190-9622(25)00377.
    PubMed    
    
    
    
17. CHANG CC, Lo SW, Chang HC, Song J, et al
    CTLA-4 inhibitors are associated with a higher risk of cardiovascular events than PD-1 inhibitors in Patients with Melanoma.
    J Am Acad Dermatol. 2025 Feb 27:S0190-9622(25)00370.
    PubMed    
    
    
    
18. ARISTIZABAL MA, Evans LA, Pincelli TP, Degesys CA, et al
    Cutaneous Melanoma Trends and Disparities in Florida: A Decade of Incidence, Mortality, and Workforce Data.
    J Am Acad Dermatol. 2025 Feb 24:S0190-9622(25)00347.
    PubMed    
    
    
    
19. RICARDO JW, Lipner SR
    Nail unit melanoma: Navigating patient and dermatologist worry Reply to "Melanoma and Worry".
    J Am Acad Dermatol. 2025 Feb 24:S0190-9622(25)00362.
    PubMed    
    
    
    
20. GASEK N, Zhou AE, Gronbeck C, Jain NP, et al
    Minimally-invasive modalities for non-melanoma skin cancer Part II: Treatment.
    J Am Acad Dermatol. 2025 Feb 21:S0190-9622(25)00320.
    PubMed     Abstract available
    
    
    
21. CHEN J, Zhou Q
    Incorporating Regional Variability and Demographic Insights into Melanoma Public Health Strategies.
    J Am Acad Dermatol. 2025 Feb 17:S0190-9622(25)00308.
    PubMed    
    
    
    
22. ZHANG H, Sun Y
    Reply: "Incorporating Regional Variability and Demographic Insights into Melanoma Public Health Strategies".
    J Am Acad Dermatol. 2025 Feb 17:S0190-9622(25)00309.
    PubMed    
    
    
    
23. GIBSON FT, Ran NA, Schmults CD, Ruiz ES, et al
    Risk of metastasis at presentation and disease-specific death for desmoplastic and spindle cell melanoma: a SEER database analysis.
    J Am Acad Dermatol. 2025 Feb 5:S0190-9622(25)00194.
    PubMed    
    
    
    January 2025
24. VALDES MORALES KL, Frankel D, Trifoi MD, Lin SK, et al
    Nail Unit Melanoma Treated with Mohs Micrographic Surgery: Technique, Local Recurrence Rate, and Surgical Outcomes.
    J Am Acad Dermatol. 2025 Jan 21:S0190-9622(25)00102.
    PubMed     Abstract available
    
    
    
25. THAKKER S, Jaguan D, Belzberg M, Gulati N, et al
    Acral Lentiginous Melanoma. Part I. Epidemiology, Etiology, Clinical Presentation, and Diagnosis.
    J Am Acad Dermatol. 2025 Jan 8:S0190-9622(25)00011.
    PubMed     Abstract available
    
    
    
26. JAGUAN D, Thakker S, Belzberg M, Gulati N, et al
    Acral Lentiginous Melanoma. Part II. Staging, Surgical Management, The Role of Systemic Therapy, Shortcomings and Future Directions.
    J Am Acad Dermatol. 2025 Jan 7:S0190-9622(25)00012.
    PubMed     Abstract available
    
    
    December 2024
27. HEYMANN WR
    Melanoma and Worry.
    J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03373.
    PubMed    
    
    
    
28. LIN S, Madan V, Joel MZ, Qiu C, et al
    Efficacy of shave (tangential) biopsies in melanoma diagnosis: A cross-sectional study.
    J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03375.
    PubMed    
    
    
    
29. ROHAN TZ, Mandel J, Banner L, Zachian R, et al
    The Risk of Developing Second Primary Malignancies in Cutaneous Melanoma Survivors.
    J Am Acad Dermatol. 2024 Dec 11:S0190-9622(24)03364.
    PubMed    
    
    
    
30. SWERLICK RA, Li Y, Adamson AS
    Response to Taylor et al, "Enhanced disease-specific survival in lentigo maligna melanoma patients treated with Mohs surgery over wide local excision: A retrospective cohort analysis of the Surveillance, Epidemiology, and End Results database".
    J Am Acad Dermatol. 2024 Dec 6:S0190-9622(24)03333.
    PubMed    
    
    
    
31. TOMSITZ D, Kerl K, French LE, Heinzerling L, et al
    Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients.
    J Am Acad Dermatol. 2024;91:1136-1142.
    PubMed     Abstract available
    
    
    November 2024
32. LAKE E
    JAAD Game Changers: "Pediatric melanomas often mimic benign skin lesions: A retrospective study".
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03278.
    PubMed    
    
    
    
33. KIM DY, Lin JY, Hartman RI
    Refusal of Surgery Among Cutaneous Melanoma Patients: Clinical Predictors and Impacts on Melanoma-Specific Survival.
    J Am Acad Dermatol. 2024 Nov 26:S0190-9622(24)03272.
    PubMed    
    
    
    
34. SHAFIQUE N, Ertmann E, Tortorello G, Karakousis GC, et al
    Desmoplastic melanoma in the era of immune checkpoint blockade.
    J Am Acad Dermatol. 2024 Nov 25:S0190-9622(24)03251.
    PubMed    
    
    
    
35. TANG J, Cheng HR
    Insufficient evidence for association between dermatology follow-up and melanoma survival.
    J Am Acad Dermatol. 2024 Nov 21:S0190-9622(24)03241.
    PubMed    
    
    
    
36. HUANG Y, Fleming P, Fung K, Chan AW, et al
    Response to Tang et al., "Insufficient evidence for association between dermatology follow-up and melanoma survival".
    J Am Acad Dermatol. 2024 Nov 21:S0190-9622(24)03240.
    PubMed    
    
    
    
37. ROSENTHAL A, Kim JY, Juhasz ML, Conde G, et al
    Tumor Upstaging in Invasive Melanoma is Associated with Changes in Clinical Management and Worse Prognosis.
    J Am Acad Dermatol. 2024 Nov 21:S0190-9622(24)03233.
    PubMed     Abstract available
    
    
    
38. TAYLOR MA, Sharma D, Thomas S, Wei EX, et al
    Reduced Disease-Specific Mortality in Melanoma in situ Patients Treated with Mohs Surgery over Wide Local Excision: A Study of the Surveillance, Epidemiology, and End Results Database.
    J Am Acad Dermatol. 2024 Nov 20:S0190-9622(24)03225.
    PubMed    
    
    
    
39. ZHANG Y, Wu J, Cai X, Jiang K, et al
    Nevus-associated acral melanoma has lower risk of recurrence and mortality than de novo acral melanoma: A multicenter, retrospective analysis of 482 patients.
    J Am Acad Dermatol. 2024 Nov 20:S0190-9622(24)03237.
    PubMed     Abstract available
    
    
    
40. NEUBAUER ZJK, Lipner SR
    No association between Turner syndrome and melanoma risk: A retrospective cohort study.
    J Am Acad Dermatol. 2024 Nov 19:S0190-9622(24)03220.
    PubMed    
    
    
    
41. KANTOR J
    This Month in JAAD International: February 2025: Melanoma biopsy approaches in Australia and guidelines adherence.
    J Am Acad Dermatol. 2024 Nov 19:S0190-9622(24)03229.
    PubMed    
    
    
    
42. HEYMANN WR
    Turning Our Attention to Melanoma Risk in Turner Syndrome.
    J Am Acad Dermatol. 2024 Nov 19:S0190-9622(24)03228.
    PubMed    
    
    
    
43. AHMED A, Alani O, Haraldsdottir EL, Hoyt D, et al
    A Post-Pandemic Surge of Thick Melanomas in Women: A Nationwide Study on Skin Cancer Incidence During COVID-19.
    J Am Acad Dermatol. 2024 Nov 16:S0190-9622(24)03226.
    PubMed    
    
    
    
44. ITUARTE BE, Taylor MA, Thomas SI, Sharma D, et al
    Clinical Presentations and Decreasing Incidence of Melanoma in Pediatric and AYA Patients: 76,108 Cases from a Nationally Representative Cohort.
    J Am Acad Dermatol. 2024 Nov 15:S0190-9622(24)03196.
    PubMed     Abstract available
    
    
    
45. PATTERSON A
    JAAD Game Changers: "A single-institution assessment of superficial spreading melanoma (SSM) in the pediatric population: Molecular and histopathologic features compared with adult SSM".
    J Am Acad Dermatol. 2024 Nov 14:S0190-9622(24)03206.
    PubMed    
    
    
    
46. SKELSEY MK, Loftis B, Kaufmann MD, Siegel DM, et al
    Clinical Performance of a Noninvasive Melanoma Rule-Out Test Across Fitzpatrick Skin Types.
    J Am Acad Dermatol. 2024 Nov 14:S0190-9622(24)03157.
    PubMed    
    
    
    
47. HIRNER JP, Rajeh A, Semenov YR, Kwatra SG, et al
    A retrospective cohort study of the time between prior antibiotics and checkpoint inhibitors and association with survival in melanoma patients.
    J Am Acad Dermatol. 2024 Nov 14:S0190-9622(24)03186.
    PubMed    
    
    
    
48. TORTORELLO GN, Shafique N, Dheer A, Chu EY, et al
    Impact of 8(th) edition AJCC staging changes on sentinel lymph node biopsy practices in melanoma.
    J Am Acad Dermatol. 2024 Nov 13:S0190-9622(24)03158.
    PubMed    
    
    
    
49. DANA IN, Kurtansky NR, Pastore LM, Xu JR, et al
    Differentiating Seborrheic Keratosis from Melanoma Among Lesions Exhibiting Blue-White Veil: A Retrospective Study.
    J Am Acad Dermatol. 2024 Nov 9:S0190-9622(24)03118.
    PubMed     Abstract available
    
    
    
50. STULL CM, Clark D, Parker T, Idriss MH, et al
    Current and emerging intralesional immunotherapies in cutaneous oncology.
    J Am Acad Dermatol. 2024;91:910-921.
    PubMed     Abstract available
    
    
    October 2024
51. SHARMA AN, Arora JS, Vidal NY, Demer AM, et al
    Tumor characteristics and outcomes of malignant melanomas on the genitalia.
    J Am Acad Dermatol. 2024 Oct 22:S0190-9622(24)03028.
    PubMed    
    
    
    
52. HUANG CT, Liao YH, Liau JY, Chu CY, et al
    Pretreatment neutrophil-to-lymphocyte ratio predicts survival in primary mucosal melanoma.
    J Am Acad Dermatol. 2024 Oct 22:S0190-9622(24)03026.
    PubMed    
    
    
    
53. ALVAREZ GV, Liao KP, Wehner MR, Rogge MN, et al
    Melanoma risk in Turner Syndrome: a case-control study in SEER-Medicare.
    J Am Acad Dermatol. 2024 Oct 9:S0190-9622(24)02961.
    PubMed    
    
    
    
54. GONTIJO JRV, Nelson J, Diehl K, Korcheva VB, et al
    Thin and in situ melanomas of unfavorable prognosis: a retrospective observational analysis of local recurrence, metastasis, and death in early-stage disease.
    J Am Acad Dermatol. 2024 Oct 8:S0190-9622(24)02964.
    PubMed    
    
    
    
55. HO G, Collgros H, Sinz C, Melhoranse-Gouveia B, et al
    Remote cutaneous confocal microscopy: A multicentric prospective study evaluating diagnostic accuracy for melanoma and keratinocyte carcinoma in tertiary settings.
    J Am Acad Dermatol. 2024 Oct 8:S0190-9622(24)02956.
    PubMed     Abstract available
    
    
    
56. MONCAYO AK, Grossman D, Kim CC, Hartman RI, et al
    Response to Bass et al's "Significant discordance in DermTech test results when paired with histopathology: Caveat emptor".
    J Am Acad Dermatol. 2024;91:e101-e102.
    PubMed    
    
    
    September 2024
57. SUN Y, Shen Y, Liu Q, Zhang H, et al
    Global Trends in Melanoma Burden: A Comprehensive Analysis from the Global Burden of Disease Study, 1990-2021.
    J Am Acad Dermatol. 2024 Sep 27:S0190-9622(24)02893.
    PubMed     Abstract available
    
    
    
58. ZHANG Y, Chung J, Chen R, Malhotra S, et al
    Testing the ability of artificial intelligence chatbots and dermatologic diagnosis mobile applications to diagnose melanoma and seborrheic keratosis.
    J Am Acad Dermatol. 2024 Sep 24:S0190-9622(24)02882.
    PubMed    
    
    
    
59. TAYLOR MA, Sharma D, Thomas SI, Ituarte BE, et al
    Examining Racial and Ethnic Disparities in Cutaneous Melanoma of the Head and Neck.
    J Am Acad Dermatol. 2024 Sep 15:S0190-9622(24)02829.
    PubMed    
    
    
    
60. TAYLOR MA, Sharma D, Thomas S, Wei EX, et al
    Improved disease-specific survival in head and neck cutaneous melanomas treated with Mohs surgery over wide local excision in the United States.
    J Am Acad Dermatol. 2024 Sep 13:S0190-9622(24)02724.
    PubMed    
    
    
    
61. LI AT, Xu JX, Blah TR, Lo SN, et al
    Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: implications for systemic therapy.
    J Am Acad Dermatol. 2024 Sep 5:S0190-9622(24)02768.
    PubMed     Abstract available
    
    
    
62. GREEN LJ, Brouha B, Bhatia N
    Response to Bass et al's "Significant discordance in DermTech test results when paired with histopathology: Caveat emptor".
    J Am Acad Dermatol. 2024;91:e79.
    PubMed    
    
    
    August 2024
63. EVERDELL E, Borok J, Deutsch A, Ren Z, et al
    ATLAS: A positive, high-yield review of patient symptoms most significantly associated with melanoma recurrence.
    J Am Acad Dermatol. 2024 Aug 26:S0190-9622(24)02732.
    PubMed     Abstract available
    
    
    
64. HOANG M, Mirza FN, Weinstock MA, Qureshi AA, et al
    Incidence of melanoma and its subtypes by census tract-level socioeconomic status: a United States population-based cohort analysis.
    J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02729.
    PubMed    
    
    
    
65. NUGENT S, Deitermann AM, Lin SK, Lewis DJ, et al
    Factors Associated with Adherence to Skin Self-examination Recommendations for Melanoma Patients: A Prospective Cohort Study.
    J Am Acad Dermatol. 2024 Aug 17:S0190-9622(24)02670.
    PubMed    
    
    
    
66. SRIVASTAVA D
    Response to Bennett, "Correction to excision margins for melanoma in situ on the head and neck".
    J Am Acad Dermatol. 2024 Aug 16:S0190-9622(24)02663.
    PubMed    
    
    
    
67. BENNETT R
    Correction to excision margins for melanoma in situ on the head and neck.
    J Am Acad Dermatol. 2024 Aug 16:S0190-9622(24)02662.
    PubMed    
    
    
    
68. WANG J, Hu G
    Boosting GPT-4V's Accuracy in Dermoscopic Classification with Few-Shot Learning. Comment on "Can ChatGPT vision diagnose melanoma? An exploratory diagnostic accuracy study(").
    J Am Acad Dermatol. 2024 Aug 2:S0190-9622(24)02572.
    PubMed    
    
    
    July 2024
69. LATONI DI, Semenov YR, Tsao H
    Differential Time Series Analysis shows Decelerations in Melanoma Mortality Prior to the Widespread Use of Highly Effective Therapies.
    J Am Acad Dermatol. 2024 Jul 20:S0190-9622(24)02533.
    PubMed     Abstract available
    
    
    
70. DACUNHA M, Tassavor M, South MB, Coldiron B, et al
    Improving Melanoma Reporting: The Ohio Model.
    J Am Acad Dermatol. 2024 Jul 19:S0190-9622(24)02495.
    PubMed    
    
    
    
71. FRIEDMAN A
    JAAD Game Changers: "Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort".
    J Am Acad Dermatol. 2024 Jul 17:S0190-9622(24)02501.
    PubMed    
    
    
    
72. TUPPER CJ, Cogua LM, Silberstein PT
    Increasing Survival for Melanoma with Bony Metastases in the Era of Novel Therapies: A Population-Based Retrospective Analysis.
    J Am Acad Dermatol. 2024 Jul 16:S0190-9622(24)02493.
    PubMed    
    
    
    
73. TAYE M, Machado KTL, Blalock T, Krueger LD, et al
    Differences in Skin Cancer Surveillance Among Patients with Non-melanoma Skin Cancer by Race: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Jul 6:S0190-9622(24)01036.
    PubMed    
    
    
    
74. TAYLOR MA, Thomas SI, Fernandez JM, Wackel M, et al
    Enhanced Disease-Specific Survival in Lentigo Maligna Melanoma Patients Treated with Mohs Surgery over Wide Local Excision: A Retrospective Cohort Analysis of the Surveillance, Epidemiology, and End Results Database.
    J Am Acad Dermatol. 2024 Jul 3:S0190-9622(24)00998.
    PubMed    
    
    
    June 2024
75. LAKE E
    JAAD Game Changers: "Functional surgery versus amputation for in situ or minimally invasive nail melanoma: A meta-analysis".
    J Am Acad Dermatol. 2024 Jun 29:S0190-9622(24)00983.
    PubMed    
    
    
    
76. LAKE E
    JAAD Game Changers: "Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field".
    J Am Acad Dermatol. 2024 Jun 29:S0190-9622(24)00985.
    PubMed    
    
    
    
77. JEAN-PIERRE P, Jacob Scheinkman R, Nouri K
    No significant disparities in non-melanoma skin cancer between Latino and White cohorts in Miami, Florida: a single-center retrospective analysis.
    J Am Acad Dermatol. 2024 Jun 22:S0190-9622(24)00954.
    PubMed    
    
    
    
78. GRANT-KELS JM
    JAAD Game Changers: "Nevoid melanoma: A study of 43 cases with emphasis on growth pattern".
    J Am Acad Dermatol. 2024 Jun 14:S0190-9622(24)00923.
    PubMed    
    
    
    
79. GRANT-KELS JM
    JAAD Game Changers: "Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011".
    J Am Acad Dermatol. 2024 Jun 14:S0190-9622(24)00920.
    PubMed    
    
    
    
80. UGWU N, Hawryluk EB, Weiss J
    Epidemiological Patterns and Survival Outcomes in 1,666 Cases of Malignant Melanomas Arising from Giant Pigmented Nevi.
    J Am Acad Dermatol. 2024 Jun 5:S0190-9622(24)00845.
    PubMed    
    
    
    May 2024
81. CHEN ML, Rezaei SJ, Kim J, Rodriguez C, et al
    Incidence of Suicide Among Melanoma and Non-Keratinocyte Skin Cancer Patients in the US, 2000-2020.
    J Am Acad Dermatol. 2024 May 18:S0190-9622(24)00787.
    PubMed    
    
    
    
82. BRODELL RT
    JAAD Game Changers: "Screening, early detection, education, and trends for melanoma: Current status (2007-2013) and future directions Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology".
    J Am Acad Dermatol. 2024 May 18:S0190-9622(24)00795.
    PubMed    
    
    
    
83. SHAH P, Trepanowski N, Grant-Kels JM, LeBoeuf M, et al
    Mohs Micrographic Surgery in the Surgical Treatment Paradigm of Melanoma In Situ and Invasive Melanoma: A Clinical Review of Treatment Efficacy and Ongoing Controversies.
    J Am Acad Dermatol. 2024 May 18:S0190-9622(24)00756.
    PubMed     Abstract available
    
    
    
84. FREEMAN SC, Paz Munoz E, Latour E, Lim JY, et al
    Response to Prieto et al., "RE: External validation of the Melanoma Institute Australia Sentinel Lymph Metastasis Risk Prediction Tool using the National Cancer Database".
    J Am Acad Dermatol. 2024 May 11:S0190-9622(24)00733.
    PubMed    
    
    
    
85. PRIETO PA, Goldberg MS, Martin B
    RE: External validation of the Melanoma Institute Australia Sentinel Lymph Metastasis Risk Prediction Tool using the National Cancer Database.
    J Am Acad Dermatol. 2024 May 9:S0190-9622(24)00735.
    PubMed    
    
    
    April 2024
86. KOGA S, Du W, Ono D
    Response to "Can ChatGPT Vision Diagnose Melanoma? An Exploratory Diagnostic Accuracy Study.".
    J Am Acad Dermatol. 2024 Apr 27:S0190-9622(24)00671.
    PubMed    
    
    
    
87. DESAI AD, Ibrahim SJ, Samie FH
    Evaluating the benefit of immunotherapy for Stage III melanoma.
    J Am Acad Dermatol. 2024 Apr 27:S0190-9622(24)00679.
    PubMed    
    
    
    
88. MONNIER J, Gouabou Foahom AC, Serdi M, Collenne J, et al
    Automated melanoma detection. An algorithm inspired from human intelligence characterizing disordered pattern of melanocytic lesions improving a convolutional neural network.
    J Am Acad Dermatol. 2024 Apr 11:S0190-9622(24)00630.
    PubMed    
    
    
    
89. WANG E, Ahad T, Liu YA, Lee TK, et al
    Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: A retrospective cohort study.
    J Am Acad Dermatol. 2024;90:759-766.
    PubMed     Abstract available
    
    
    
90. COHEN Y, Jaberi M, Litvinov IV, Shamout Y, et al
    Novel suturing technique for reduced electrocautery in excisional procedures for non-melanoma skin cancer.
    J Am Acad Dermatol. 2024;90:e131-e132.
    PubMed    
    
    
    March 2024
91. FUNCHAIN P, Ni Y, Heald B, Bungo B, et al
    Germline Cancer Susceptibility in Individuals with Melanoma.
    J Am Acad Dermatol. 2024 Mar 19:S0190-9622(24)00504.
    PubMed     Abstract available
    
    
    
92. BANNER L, Rohan TZ, Zachian R, Gross T, et al
    Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A SEER database analysis.
    J Am Acad Dermatol. 2024 Mar 19:S0190-9622(24)00505.
    PubMed    
    
    
    
93. MATTHEWS NH, Hamad J, Henderson JB, Weinstock MA, et al
    Projected burden of melanoma clinical surveillance in the United States.
    J Am Acad Dermatol. 2024 Mar 8:S0190-9622(24)00476.
    PubMed    
    
    
    
94. TUPPER CJ, Clausen MC, Cogua LM, Silberstein PT, et al
    Improved Survival Outcomes for Melanoma of Unknown Primary in the Era of Novel Therapies: A Population-Based Retrospective Analysis.
    J Am Acad Dermatol. 2024 Mar 6:S0190-9622(24)00446.
    PubMed    
    
    
    
95. NEALE H, Plumptre I, Belazarian L, Wiss K, et al
    Guidance on screening magnetic resonance imaging decisions for congenital melanocytic nevi.
    J Am Acad Dermatol. 2024;90:e107-e108.
    PubMed    
    
    
    
96. GRANT-KELS JM
    JAAD Game Changer: Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society.
    J Am Acad Dermatol. 2024;90:674.
    PubMed    
    
    
    February 2024
97. GIULINI M, Goldust M, Grabbe S, Ludwigs C, et al
    Combining artificial intelligence and human expertise for more accurate dermoscopic melanoma diagnosis: A 2-session retrospective reader study.
    J Am Acad Dermatol. 2024 Feb 29:S0190-9622(24)00307.
    PubMed    
    
    
    
98. TORTORELLO GN, Li EH, Sharon CE, Shafique N, et al
    Pathologic Characteristics and Clinical Outcomes of Primary Dermal Melanoma.
    J Am Acad Dermatol. 2024 Feb 22:S0190-9622(24)00401.
    PubMed    
    
    
    
99. HUANG Y, Fleming P, Fung K, Chan AW, et al
    Association between dermatology follow-up and melanoma survival: a population-based cohort study.
    J Am Acad Dermatol. 2024 Feb 16:S0190-9622(24)00372.
    PubMed     Abstract available
    
    
    
100. MORR C, Jade Prechtel T, Hardacker R, Bell M, et al
     Impact of skin cancer screening on melanoma thickness and stage.
     J Am Acad Dermatol. 2024 Feb 13:S0190-9622(24)00348.
     PubMed    
     
     
     
101. KYE Y, Zhao G, Guhan S, Nunes D, et al
     Research letter: BRAF-inhibitor induced panniculitis - A systematic review.
     J Am Acad Dermatol. 2024;90:420-423.
     PubMed    
     
     
     January 2024
102. KOOPER-JOHNSON S, Kasthuri V, Homer A, Nguyen BM, et al
     Higher Risk of Melanoma-related Deaths for Patients Residing in Rural Counties: A Surveillance, Epidemiology, and End Results Program Study.
     J Am Acad Dermatol. 2024 Jan 31:S0190-9622(24)00167.
     PubMed    
     
     
     
103. CHOI ME, Jung JM, Kim DH, Won CH, et al
     Baseline Serum Neutrophil-to-Lymphocyte Ratio in Acral Melanoma Compared to Non-Acral Melanoma and its Prognostic Significance.
     J Am Acad Dermatol. 2024 Jan 23:S0190-9622(24)00103.
     PubMed     Abstract available
     
     
     
104. TATE JA, Matsumoto A, Greif C, Lim J, et al
     Excision Margins for Melanoma in Situ on the Head and Neck - A Single-Center 10-year Retrospective Review of Treatment with Mohs Micrographic Surgery.
     J Am Acad Dermatol. 2024 Jan 20:S0190-9622(24)00102.
     PubMed     Abstract available
     
     
     
105. SHIFAI N, van Doorn R, Malvehy J, Sangers T, et al
     Can ChatGPT Vision Diagnose Melanoma? An Exploratory Diagnostic Accuracy Study.
     J Am Acad Dermatol. 2024 Jan 18:S0190-9622(24)00076.
     PubMed    
     
     
     
106. VIKSTROM S, Syriopoulou E, Andersson TM, Eriksson H, et al
     Loss in life expectancy in Patients with Stage II-III cutaneous melanoma in Sweden: a population-based cohort study.
     J Am Acad Dermatol. 2024 Jan 11:S0190-9622(24)00056.
     PubMed     Abstract available
     
     
     
107. TIMURKAYNAK O, Gonenli G
     Response to Young JN et al.'s "The utility of ChatGPT in generating patient-facing and clinical responses for melanoma".
     J Am Acad Dermatol. 2024 Jan 10:S0190-9622(24)00060.
     PubMed    
     
     
     
108. HEKLER A, Maron RC, Haggenmuller S, Schmitt M, et al
     Using Multiple Real-World Dermoscopic Photographs of One Lesion Improves Melanoma Classification via Deep Learning.
     J Am Acad Dermatol. 2024 Jan 8:S0190-9622(24)00048.
     PubMed    
     
     
     
109. NAVARRETE-DECHENT C, Jaimes N, Dusza SW, Liopyris K, et al
     Perifollicular linear projections: A dermatoscopic criterion for the diagnosis of lentigo maligna on the face.
     J Am Acad Dermatol. 2024;90:52-57.
     PubMed     Abstract available
     
     
     December 2023
110. BERK-KRAUSS J, Sharma M, Polsky D, Geller AC, et al
     Cutaneous Melanoma Incidence - Evidence of a Flattening Curve.
     J Am Acad Dermatol. 2023 Dec 10:S0190-9622(23)03288.
     PubMed    
     
     
     
111. HAGSTROM M, Dhillon S, Fumero-Velazquez M, Olivares S, et al
     A reappraisal of the epidemiology of Spitz neoplasms in the molecular era: A retrospective cohort study.
     J Am Acad Dermatol. 2023;89:1185-1191.
     PubMed     Abstract available
     
     
     
112. KOOPER-JOHNSON SB, Weber M, Eichtadt S, Nguyen BM, et al
     Limited commercialization of artificial intelligence technology in the diagnosis of pigmented lesions despite explosive growth in published programs.
     J Am Acad Dermatol. 2023;89:1246-1248.
     PubMed    
     
     
     
113. WAGNER NB, Knierim SM, Luttermann F, Metzler G, et al
     Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A
     J Am Acad Dermatol. 2023 Dec 1:S0190-9622(23)03250.
     PubMed     Abstract available
     
     
     
114. FERNANDEZ JM, Mata EM, Plampton K, Whitley MJ, et al
     Melanoma Characteristics and Overall Survival Predictors in American Indians and Alaska Natives: An Analysis of the National Cancer Database from 2004 to 2018.
     J Am Acad Dermatol. 2023 Dec 1:S0190-9622(23)03254.
     PubMed    
     
     
     November 2023
115. FERNANDEZ JM, Evans TD, Schissel M, Siller A Jr, et al
     Racial and ethnic differences in time to definitive surgery for melanoma: A retrospective study from the National Cancer Database.
     J Am Acad Dermatol. 2023 Nov 30:S0190-9622(23)03251.
     PubMed    
     
     
     
116. PAN CX, Liu M, Lau CB, Lau WC, et al
     Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors.
     J Am Acad Dermatol. 2023 Nov 29:S0190-9622(23)03239.
     PubMed    
     
     
     
117. HAWRYLUK EB, Moustafa D, Barry KK, Bahrani E, et al
     Risk Factors and Outcomes of Melanoma in Children and Adolescents: A Retrospective Multicenter Study.
     J Am Acad Dermatol. 2023 Nov 29:S0190-9622(23)03238.
     PubMed     Abstract available
     
     
     
118. FALDETTA C, Kaleci S, Chester J, Ruini C, et al
     Melanoma clinicopathological groups characterized and compared with dermoscopy and reflectance confocal microscopy.
     J Am Acad Dermatol. 2023 Nov 19:S0190-9622(23)03014.
     PubMed     Abstract available
     
     
     
119. MAGHFOUR J, Li P, Piontkowski A, Ozog D, et al
     Melanoma Incidence and Mortality: Exploring the Impact of Regional UV Radiation and Socioeconomic Status in the Context of Breslow Thickness.
     J Am Acad Dermatol. 2023 Nov 8:S0190-9622(23)03181.
     PubMed    
     
     
     
120. CLARK P, Howard H, Garrett E, Waters P, et al
     Health inequities in melanoma: A scoping review.
     J Am Acad Dermatol. 2023 Nov 2:S0190-9622(23)02892.
     PubMed    
     
     
     
121. KIM DY, Swetter SM, Huhmann L, Dizon MP, et al
     Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among Veteran cutaneous melanoma patients.
     J Am Acad Dermatol. 2023 Nov 2:S0190-9622(23)03089.
     PubMed    
     
     
     
122. TOMAS-VELAZQUEZ A, Lopez-Gutierrez JC, Reyes-Mugica M, Salgado CM, et al
     Serum levels of S-100 protein are directly proportional to the size, number, thickness and degree of cellularity of congenital melanocytic nevi.
     J Am Acad Dermatol. 2023;89:1074-1077.
     PubMed    
     
     
     
123. AHMED F, Fisher MJ, Snyder KM, Smith K, et al
     Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population.
     J Am Acad Dermatol. 2023;89:1066-1068.
     PubMed    
     
     
     
124. KIM DY, Christopher Dee E, Cheng I, Hartman RI, et al
     Advanced melanoma presentation and disease-specific survival disparities among disaggregated Asian American, Native Hawaiian, and Pacific Islander populations.
     J Am Acad Dermatol. 2023 Nov 1:S0190-9622(23)03090.
     PubMed    
     
     
     October 2023
125. RAVICHANDRAN S, Briskin I, Arbesman J
     Increased diagnostic interval for nodular melanomas does not associate with increased tumor thickness or staging: results from a single-center retrospective chart review.
     J Am Acad Dermatol. 2023 Oct 28:S0190-9622(23)03088.
     PubMed    
     
     
     
126. EVERDELL E, Shah H, Parisi R, Feustel PJ, et al
     Non-visibility of Suspicious Lesions by Patients Leads to Later Detection of Melanoma: A Retrospective Analysis.
     J Am Acad Dermatol. 2023 Oct 4:S0190-9622(23)02888.
     PubMed    
     
     
     
127. FERNANDEZ JM, Koblinski JE, Dahak S, Curiel-Lewandrowski C, et al
     Gender Differences in Pediatric and Adolescent Melanoma: A Retrospective Analysis of 4,645 Cases.
     J Am Acad Dermatol. 2023 Oct 4:S0190-9622(23)02866.
     PubMed     Abstract available
     
     
     
128. WAN G, Leung BW, DeSimone MS, Nguyen N, et al
     Development and Validation of Time-to-Event Models to Predict Metastatic Recurrence of Localized Cutaneous Melanoma.
     J Am Acad Dermatol. 2023 Oct 3:S0190-9622(23)02881.
     PubMed     Abstract available
     
     
     
129. YUMEEN S, Mirza FN, Mirza HN, Zogg CK, et al
     Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database.
     J Am Acad Dermatol. 2023;89:843-846.
     PubMed    
     
     
     
130. KRENGEL S, Ott H, Waelchli R
     Recommendations for routine magnetic resonance imaging in children with congenital melanocytic nevi need revision Comment to Neale et al., J Am Acad Dermatol. 87(5):1060-1068.
     J Am Acad Dermatol. 2023;89:e153-e154.
     PubMed    
     
     
     September 2023
131. WEI AH, Fane LS, Tripathi R, Bordeaux JS, et al
     Differences in presentation of cutaneous melanoma among Asian American and Pacific Islander patients.
     J Am Acad Dermatol. 2023 Sep 26:S0190-9622(23)02868.
     PubMed    
     
     
     
132. WEI AH, Zheng DX, Cullison CR, Scott JF, et al
     Incidence and characteristics of acral lentiginous melanoma in Asian Americans and Pacific Islanders.
     J Am Acad Dermatol. 2023 Sep 19:S0190-9622(23)02828.
     PubMed    
     
     
     
133. TAN SX, Aung TN, Claeson M, Acs B, et al
     Automated scoring of tumour infiltrating lymphocytes informs risk of death from thin melanoma: a nested case-case study.
     J Am Acad Dermatol. 2023 Sep 18:S0190-9622(23)02833.
     PubMed    
     
     
     
134. NI Y, Watts CG, Scolyer RA, Madronio C, et al
     Prognosis for people with multiple primary melanomas compared with a single primary melanoma.
     J Am Acad Dermatol. 2023 Sep 13:S0190-9622(23)02693.
     PubMed    
     
     
     
135. WU Q, Pan J, Lin W, Zhao S, et al
     Clinicopathologic features, delayed diagnosis and survival in amelanotic acral melanoma: a comparative study with pigmented melanoma.
     J Am Acad Dermatol. 2023 Sep 8:S0190-9622(23)02677.
     PubMed    
     
     
     
136. LIN JY, Wang J, Mishra K, Osmani S, et al
     Non-Melanoma Skin Cancer in Skin of Color Solid Organ Transplant Recipients.
     J Am Acad Dermatol. 2023 Sep 7:S0190-9622(23)02678.
     PubMed    
     
     
     
137. GRANT-KELS JM
     JAAD Game Changers: Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.
     J Am Acad Dermatol. 2023 Sep 7:S0190-9622(23)02674.
     PubMed    
     
     
     
138. JILANI S, D'Amiano NM, Thompson KG, Ellis J, et al
     Factors Affecting Follow-Up Adherence Following Mohs Micrographic Surgery in Patients with Non-Melanoma Skin Cancer: A Retrospective Chart Review.
     J Am Acad Dermatol. 2023 Sep 5:S0190-9622(23)02669.
     PubMed    
     
     
     
139. KIM U, Hoehn R, Schwartz GK, Cullen J, et al
     Evaluating disruptions in melanoma diagnosis resulting from the COVID-19 pandemic from a community-based perspective.
     J Am Acad Dermatol. 2023 Sep 2:S0190-9622(23)02659.
     PubMed    
     
     
     
140. COSTELLO CM, Dusza SW, Marghoob AA, Halpern AC, et al
     Melanoma Screening and Public Education for Minority Populations in the United States.
     J Am Acad Dermatol. 2023 Sep 2:S0190-9622(23)02663.
     PubMed    
     
     
     
141. ANVERY N, Kang B, Christensen RE, Dirr MA, et al
     Minimum thresholds deemed acceptable by patients and physicians for sensitivity and specificity of mobile skin cancer screening algorithms.
     J Am Acad Dermatol. 2023;89:595-597.
     PubMed    
     
     
     
142. CHOI S, Mulvaney P
     Evaluating the landscape of discount and patient assistance programs for topical sunscreen products in the United States.
     J Am Acad Dermatol. 2023;89:580-582.
     PubMed    
     
     
     August 2023
143. SORENSEN R
     Impact of scalp location on survival in head and neck melanoma: A retrospective cohort study.
     J Am Acad Dermatol. 2023 Aug 26:S0190-9622(23)02633.
     PubMed    
     
     
     
144. XIONG DD, Bordeaux J
     The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and outcomes of invasive cutaneous melanoma: a retrospective national cohort study.
     J Am Acad Dermatol. 2023 Aug 23:S0190-9622(23)02595.
     PubMed     Abstract available
     
     
     
145. BRODELL RT
     Primary dermal melanoma: A unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma: A clinical, histologic, and gene expression-profiling study.
     J Am Acad Dermatol. 2023 Aug 16:S0190-9622(23)02515.
     PubMed    
     
     
     
146. ROSTER K, Rajeh A, Wu F, Wan G, et al
     Recurrence and Survival in Early-stage Acral Lentiginous Melanoma, A Retrospective Analysis.
     J Am Acad Dermatol. 2023 Aug 13:S0190-9622(23)02494.
     PubMed    
     
     
     
147. PAN CX, Lau WC, Kim DY, Lau CB, et al
     Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation.
     J Am Acad Dermatol. 2023 Aug 8:S0190-9622(23)02422.
     PubMed    
     
     
     
148. EL SHAROUNI MA, Lo SN, Scolyer RA, van Gils CH, et al
     Reply to: "Estrogen could also play a key role in the development of pediatric melanoma".
     J Am Acad Dermatol. 2023;89:e97-e98.
     PubMed    
     
     
     July 2023
149. AMARAL T, Pop OT, Chatziioannou E, Sinnberg T, et al
     EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
     J Am Acad Dermatol. 2023 Jul 22:S0190-9622(23)02392.
     PubMed    
     
     
     
150. FREEMAN SC, Munoz EP, Latour E, Lim JY, et al
     External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database.
     J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01350.
     PubMed     Abstract available
     
     
     
151. HOANG MP, Karpinski P, Zuniga-Castillo M, Foreman RK, et al
     Histologic Margin Status is a Predictor of Relapse in Lentigo Maligna Melanoma.
     J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01349.
     PubMed     Abstract available
     
     
     
152. UGWU N, Cheraghlou S, Weiss J
     Primary Merkel Cell Carcinoma Is Associated with Increased, Extended Risk of Subsequent Melanoma and Non-Epithelial Skin Cancer.
     J Am Acad Dermatol. 2023 Jul 12:S0190-9622(23)01345.
     PubMed    
     
     
     
153. FERNANDEZ JM, Mata EM, Bubic BN, Kwan KR, et al
     Racial and ethnic differences in males with melanoma: A retrospective cohort study of 205,125 cases from the National Cancer Database.
     J Am Acad Dermatol. 2023 Jul 11:S0190-9622(23)01105.
     PubMed    
     
     
     
154. MUNOZ EP, Patel SP, Leachman SA, Yu NY, et al
     Minority Enrollment in Melanoma Clinical Trials.
     J Am Acad Dermatol. 2023 Jul 5:S0190-9622(23)01263.
     PubMed    
     
     
     
155. MEVES A, Todd A, Johnson EF
     Tumor width and calculated tumor area do not outperform Breslow thickness in predicting sentinel lymph node biopsy positivity.
     J Am Acad Dermatol. 2023;89:188-190.
     PubMed    
     
     
     
156. SMITH B, Smith JE, Demanelis K, Ferris LK, et al
     Changes in skin cancer screening rates in the United States from 2005 to 2015.
     J Am Acad Dermatol. 2023;89:142-145.
     PubMed    
     
     
     
157. MORGAN FC, Yehia L, McDonald C, Martinez-Agosto JA, et al
     Characterizing dermatologic findings among patients with PTEN hamartoma tumor syndrome: Results of a multicenter cohort study.
     J Am Acad Dermatol. 2023;89:90-98.
     PubMed     Abstract available
     
     
     June 2023
158. INGRASSIA JP, Adotama P, Stein JA, Polsky D, et al
     Re-examining melanoma secondary prevention and the role of skin self-examination.
     J Am Acad Dermatol. 2023 Jun 27:S0190-9622(23)01195.
     PubMed    
     
     
     
159. RYPKA KJ, Goldfarb N, Mansh M
     Response to the Feasibility of Kreher et al.'s "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors".
     J Am Acad Dermatol. 2023 Jun 26:S0190-9622(23)01188.
     PubMed    
     
     
     
160. PAN CX, Nambudiri VE
     Response to: "Response to Pan et al.'s 'Non-melanoma skin cancer in patients with hereditary hemochromatosis: a case-control study.'".
     J Am Acad Dermatol. 2023 Jun 12:S0190-9622(23)01099.
     PubMed    
     
     
     
161. BARRY R, Murray G, Hazel K, Ryan J, et al
     Response to Pan et al.'s "Non-melanoma skin cancer in patients with hereditary hemochromatosis: a case-control study.".
     J Am Acad Dermatol. 2023 Jun 12:S0190-9622(23)01100.
     PubMed    
     
     
     
162. ABRANTES T, Robbins A, Kahn B, Yumeen S, et al
     Understanding melanoma in situ - lentigo maligna surgical treatment terminology and guideline adherence, a targeted review.
     J Am Acad Dermatol. 2023 Jun 10:S0190-9622(23)01084.
     PubMed     Abstract available
     
     
     
163. CHANG ALS, Zaba L, Kwong BY
     Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.
     J Am Acad Dermatol. 2023;88:1243-1255.
     PubMed     Abstract available
     
     
     
164. LEUNG BW, Wan G, Nguyen N, Rashdan H, et al
     Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
     J Am Acad Dermatol. 2023;88:1265-1270.
     PubMed     Abstract available
     
     
     May 2023
165. LIM RK, Weinstock MA
     Racial disparities in diagnosis of invasive melanoma among veterans: A comparative analysis with the Surveillance, Epidemiology, and End Results Program.
     J Am Acad Dermatol. 2023 May 29:S0190-9622(23)00985.
     PubMed    
     
     
     
166. RAJEH A, Wan G, Roster K, Rashdan H, et al
     Underuse of sentinel lymph node biopsy for early-stage melanoma.
     J Am Acad Dermatol. 2023 May 25:S0190-9622(23)00975.
     PubMed    
     
     
     
167. KO MJ, Tsai WC, Tsai PH, Hsu LY, et al
     Ultraviolet B Phototherapy Does Not Increase the Risk of Skin Cancer Among Patients with Atopic Dermatitis: A Population-Based Retrospective Cohort Study.
     J Am Acad Dermatol. 2023 May 24:S0190-9622(23)00977.
     PubMed     Abstract available
     
     
     
168. HEERFORDT IM, Philipsen PA, Andersen JD, Langhans L, et al
     RNA analysis of tape strips to rule out melanoma in lesions clinically assessed as cutaneous malignant melanoma: A diagnostic study.
     J Am Acad Dermatol. 2023 May 22:S0190-9622(23)00971.
     PubMed     Abstract available
     
     
     
169. FANE LS, Wei AH, Tripathi R, Bordeaux JS, et al
     Asian American and Pacific Islander patients with melanoma have increased odds of treatment delays: a cross-sectional study.
     J Am Acad Dermatol. 2023 May 22:S0190-9622(23)00969.
     PubMed     Abstract available
     
     
     
170. KIM DY, Marchetti MA, Hartman RI
     Differences in thickness-specific incidence of cutaneous melanoma by county type in the United States, 2010-2019.
     J Am Acad Dermatol. 2023 May 17:S0190-9622(23)00905.
     PubMed    
     
     
     
171. YOUNG JN, O'Hagan R, Poplausky D, Levoska MA, et al
     The utility of ChatGPT in generating patient-facing and clinical responses for melanoma.
     J Am Acad Dermatol. 2023 May 17:S0190-9622(23)00908.
     PubMed    
     
     
     
172. ZHANG S, Tang K, Wan G, Nguyen N, et al
     Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
     J Am Acad Dermatol. 2023;88:1024-1032.
     PubMed     Abstract available
     
     
     
173. JOEL MZ, Tripathi R, Scott JF
     Predictors of receipt of sentinel lymph node biopsy in patients with malignant adnexal tumors of the skin.
     J Am Acad Dermatol. 2023;88:1179-1182.
     PubMed    
     
     
     
174. FELMINGHAM C, Pan Y, Kok Y, Kelly J, et al
     Improving skin cancer management with ARTificial intelligence: A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting.
     J Am Acad Dermatol. 2023;88:1138-1142.
     PubMed    
     
     
     
175. SHI K, Zhang B, Kong BY, Zhang Y, et al
     Distinct genomic features in a retrospective cohort of mucosal, acral, and vulvovaginal melanomas.
     J Am Acad Dermatol. 2023;88:1051-1059.
     PubMed     Abstract available
     
     
     
176. CAI ED, Swetter SM, Sarin KY
     Association of multiple primary melanomas with malignancy risk: A population-based analysis of entries from the Surveillance, Epidemiology, and End Results program database during 1973-2014.
     J Am Acad Dermatol. 2023;88:e211-e219.
     PubMed     Abstract available
     
     
     April 2023
177. AZOULAY L, St-Jean A, Dahl M, Quail J, et al
     Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multi-site population-based cohort study.
     J Am Acad Dermatol. 2023 Apr 25:S0190-9622(23)00735.
     PubMed     Abstract available
     
     
     
178. SHANNON AB, Karakousis GC
     The impact of the COVID-19 pandemic on new diagnoses of melanoma: a response to additional multi-institution and international reports.
     J Am Acad Dermatol. 2023 Apr 22:S0190-9622(23)00732.
     PubMed    
     
     
     
179. DRUMM C, Griffin C, Van Baarsel S, Quigley C, et al
     Response to Trepanowski et al.'s "Delays in melanoma presentation during the COVID-19 pandemic: a nationwide multi-institutional cohort study".
     J Am Acad Dermatol. 2023 Apr 21:S0190-9622(23)00733.
     PubMed    
     
     
     
180. CHOI ME, Yang HJ, Won CH, Chang SE, et al
     Differences in the Tumor Immunity-related Gene Expression Profile Between Acral Lentiginous and Non-acral Melanoma.
     J Am Acad Dermatol. 2023 Apr 19:S0190-9622(23)00712.
     PubMed    
     
     
     
181. FANE LS, Wei AH, Tripathi R, Bordeaux JS, et al
     Disparities between Asian groups in time to melanoma treatment: a cross-sectional study.
     J Am Acad Dermatol. 2023 Apr 11:S0190-9622(23)00589.
     PubMed    
     
     
     
182. HARVEY JA, Smith JF, Berry NA, Butterfield RJ, et al
     The influence of dermoscopy education over 14 years at a single institution: A retrospective cohort study.
     J Am Acad Dermatol. 2023;88:906-908.
     PubMed    
     
     
     March 2023
183. CRUM OM, Campbell EH, Reinhart JP, Proffer SL, et al
     Incidence Trends of Melanoma among Young Adults: An Epidemiologic Study in Olmsted County, Minnesota.
     J Am Acad Dermatol. 2023 Mar 29:S0190-9622(23)00518.
     PubMed    
     
     
     
184. MATA EM, Trinidad N, Blue E, Lobl M, et al
     Disparities in melanoma outcomes in urban versus rural settings: An analysis from the Nebraska Cancer Registry 2001-2016.
     J Am Acad Dermatol. 2023 Mar 20:S0190-9622(23)00450.
     PubMed    
     
     
     
185. MAGNATERRA E, Zuccaro B, Magliulo M, Venturi F, et al
     Estrogen could also play a key role in the development of pediatric melanoma.
     J Am Acad Dermatol. 2023 Mar 18:S0190-9622(23)00439.
     PubMed    
     
     
     
186. LIN EM, Lim RK, Lin S, Cho E, et al
     Disparities in Asian American Melanoma Diagnosis and Treatment from 1990-2014 -- Response to Zheng et al. "Poor melanoma outcomes and survival in Asian American and Pacific Islander patients".
     J Am Acad Dermatol. 2023 Mar 9:S0190-9622(23)00357.
     PubMed    
     
     
     
187. KIM DY, Behbahani S, Hartman RI
     Impact of COVID-19 pandemic on melanoma presentation by facility type and region in the United States.
     J Am Acad Dermatol. 2023 Mar 8:S0190-9622(23)00356.
     PubMed    
     
     
     
188. VERMARIEN-WANG J, Doeleman T, van Doorn R, Mooyaart AL, et al
     Ambiguous melanocytic lesions: A retrospective cohort study of incidence and outcome of melanocytic tumor of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferation of uncertain significance (SAMPUS) in the Netherlan
     J Am Acad Dermatol. 2023;88:602-608.
     PubMed     Abstract available
     
     
     
189. TARANTINO IS, Kwak YJ, Goldberg LH, Beroukhim K, et al
     Application of a taped gauze on the gloved hand in preparation for a pressure bandage after a Mohs micrographic surgery layer.
     J Am Acad Dermatol. 2023;88:e125-e126.
     PubMed    
     
     
     
190. LEE K
     JAAD Game Changers *: The association of indoor tanning and melanoma in adults: Systematic review and meta-analysis.
     J Am Acad Dermatol. 2023;88:749.
     PubMed    
     
     
     February 2023
191. IQBAL A, Bell MC, Merkel EA, Somani AK, et al
     The effect of tumor mitotic rate on melanoma-specific survival: A SEER population-based study of 54,598 cases.
     J Am Acad Dermatol. 2023 Feb 23:S0190-9622(23)00274.
     PubMed    
     
     
     
192. NGUYEN N, Wan G, Ugwu-Dike P, Alexander NA, et al
     Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
     J Am Acad Dermatol. 2023 Feb 22:S0190-9622(23)00204.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.